AlphaCrest Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

AlphaCrest Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-72,489	Closed	-$1.91M	–	1450
2021 Q4	$1.91M	Buy	72,489 +67,508	+1,355%	+$5.22M	0.07%	453
2021 Q3	$501K	Buy	4,981 +69	+1%	+$8.09K	0.03%	903
2021 Q2	$695K	Sell	4,912 -4,488	-48%	-$507K	0.03%	827
2021 Q1	$937K	Buy	9,400 +7,700	+453%	+$898K	0.05%	526
2020 Q4	$210K	Buy	+1,700	New	+$223K	0.02%	1067
2020 Q2	–	Sell	-2,500	Closed	-$361K	–	1176
2020 Q1	$361K	Buy	+2,500	New	+$483K	0.04%	713

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AlphaCrest Capital Management's RETA Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2022, closing a stake of 72,489 shares — an estimated $1.91M sold.

AlphaCrest Capital Management first reported a position in RETA in Q1 2020 and held it in 6 quarters. The position peaked at $1.91M in Q4 2021. 149 funds tracked by Wall St. Rank hold RETA as of Q1 2022.

AlphaCrest Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 72,489 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2022, an estimated $1.91M.
AlphaCrest Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 6 quarters.
AlphaCrest Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.91M in Q4 2021.
149 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.